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Abstract
The diaminopimelic acid pathway of lysine biosynthesis has been suggested to provide attractive targets for the
development of novel antibacterial drugs. Here we report the characterization of two enzymes from this pathway in the
human pathogen Pseudomonas aeruginosa, utilizing structural biology, biochemistry and genetics. We show that
tetrahydrodipicolinate N-succinyltransferase (DapD) from P. aeruginosa is specific for the L-stereoisomer of the amino
substrate L-2-aminopimelate, and its D-enantiomer acts as a weak inhibitor. The crystal structures of this enzyme with L-2-
aminopimelate and D-2-aminopimelate, respectively, reveal that both compounds bind at the same site of the enzyme.
Comparison of the binding interactions of these ligands in the enzyme active site suggests misalignment of the amino
group of D-2-aminopimelate for nucleophilic attack on the succinate moiety of the co-substrate succinyl-CoA as the
structural basis of specificity and inhibition. P. aeruginosa mutants where the dapA gene had been deleted were viable and
able to grow in a mouse lung infection model, suggesting that DapA is not an optimal target for drug development against
this organism. Structure-based sequence alignments, based on the DapA crystal structure determined to 1.6 A ˚ resolution
revealed the presence of two homologues, PA0223 and PA4188, in P. aeruginosa that could substitute for DapA in the P.
aeruginosa PAO1DdapA mutant. In vitro experiments using recombinant PA0223 protein could however not detect any
DapA activity.
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Introduction
Pseudomonas aeruginosa is an opportunistic pathogen that causes
persistent infections in humans. The limited reservoir of
antibacterial drugs against gram-negative bacteria, inherent
difficulties in the clinical treatment of P. aeruginosa infections and
the onset of antibiotic resistance [1] emphasize the need to identify
novel drug targets against these pathogens. Randomized transpo-
son mutagenesis screens [2] had indicated several genes from the
diaminopimelate (DAP) biosynthetic pathway to lysine in P.
aeruginosa as essential, suggesting the corresponding gene products
as potential targets for new antibacterial drugs. Similar findings
were reported for other bacterial pathogens, such as Mycobacterium
tuberculosis [3–5] and Salmonella typhymurium [6]. These observations
reinforced previous notions that this pathway is a particular
attractive target for the design of antibacterial compounds, as it is
not found in humans and provides two essential metabolites, the
amino acid lysine and its precursor, meso-diaminopimelate, a
component of the cell wall peptidoglycan in bacteria [3,7].
Dihydrodipicolinate synthase (DapA) catalyzes the first com-
mitted step of the DAP pathway, the condensation of L-aspartate-
semialdehyde and pyruvate to 4-hydroxy-2,3,4,5-tetrahydro-L,L-
dipicolinic acid, which is non-enzymatically dehydrated to yield L-
2,3-diydrodipicolinate [7,8] (Figure 1). The reaction mechanism
involves a covalent intermediate formed between the substrate
pyruvate and an invariant lysine residue at the active site [8]. The
crystal structure of Escherichia coli DapA revealed a homotetrameric
enzyme, with the subunits displaying the ubiquitous b/a barrel
fold [9]. By now structures of DapA from over 20 organisms have
been determined and the majority all show a homotetrameric
arrangement of the subunits [9–17]. However, functional
homodimeric forms of DapA have also recently been described
[18–20]. DapA is subject to allosteric feed-back regulation by L-
lysine and crystal structures of the enzyme from E. coli and P.
aeruginosa with bound lysine have revealed the structural basis for
its regulation [12,20]. The role of the active residues Lys-161, Thr-
44, Arg-138 in catalysis has been investigated for Escherichia coli
DapA identifying the proton-relay system and the mode of
enzyme-substrate interactions [21–23].
Tetrahydrodipicolinate N-succinyltransferase (DapD) catalyses
the transfer of the succinyl moiety of succinyl-CoA to the a-amino
group of tetrahydrodipicolinate, the first committed step in the
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most Gram-negative bacteria and mycobacteria [24] (Figure 1).
The crystal structures of DapD from Escherichia coli [25],
Mycobacterium tuberculosis [26] and Mycobacterium bovis [27] have
been published, although the origin of the gene for the latter has
been questioned [26]. In addition, the coordinates for DapD from
Campylobacter jejuni (2RIJ), Enterococcus feacalis (3CJ8), Brucella
melitensis (3EG4), and Yersinia pestis (3GOS) have been deposited
in the Protein Data Bank by several Structural Genomics projects.
In all these cases, DapD reveals a homotrimeric structure with the
three active sites located between adjacent subunits. The common
characteristic structural feature of DapD enzymes is a left-handed
parallel b-helix (LbH) domain. This trimeric structural module
occurs in many acyltransferases and provides binding surfaces for
the substrate acyl-CoA. DapDs typically contain additional N- and
C-terminal domains fused to the central LbH domain.
Crystallographic investigations of the binary complex of
MtDapD with succinyl-CoA [26] and of ternary complexes of
DapD [28,29] are consistent with a nucleophilic attack of the
substrate amino group on the carbonyl group of succinyl-CoA.
Comparisons of the structures of apo-DapD with that of ligand
bound DapD revealed conformational changes upon binding of
the substrates that involve several regions of the polypeptide chain
[25,28,29].
As dapA (PA1010) and dapD (PA3666) were suggested to be
essential genes in P. aeruginosa [2] we set out to characterize these
enzymes of the DAP pathway in this organism in more detail.
Furthermore we characterized a gene knockout both in vitro and in
vivo using a mouse model of acute P. aeruginosa infection. We show
that PaDapD is specific for L-aminopimelic acid (L-2AP), and that
the stereoisomer D-2-aminopimelic (D-2AP) acid is not a
substrate, but a weak inhibitor. The crystal structures of PaDapD
with L-2AP and D-2AP, respectively, reveal the structural basis for
inhibition and stereoselectivity. The in vivo knockout studies show
that P. aeruginosa mutants lacking the dapA gene are still able to
cause acute infection in mice, suggesting that this enzyme may not
be a suitable target for new antibiotics against this organism.
Materials and Methods
Construction of suicide vectors for knock out of dapA
(PA1010)
For gene replacement of dapA (PA1010) the sacB-based strategy
[30,31] was employed. In order to construct the suicide vectors for
deletion of dapA (PA1010) regions of approximately 400 bp flanking
the target genes were amplified using genomic DNA prepared from
Pseudomonas aeruginosa PAO1 (ATCC 47085) as template. Primers
404PA1010 (59-GCGACGGAATTCGGGCCGGCAGGCTGC-
CCT-39) with an EcoRI site at the 59-end and 405PA1010 (59-
GCGACGGGATCCGCAACCGCTCCTGCCGCG-39) contain-
ing a BamHI site were used for amplification of the upstream
fragment of the dapA coding sequence. Primers 406PA1010 (59-
GCGACGGGATCCTCAAGGAGCTCCACGCAA-39) contain-
ing a BamHI site and 407PA1010 (59-GCGACGAAGCTTCG-
GAAACCGTTCTCCTCG-39) with a HindIII site were used for
downstream fragment amplification. After digest with the corre-
sponding endonucleases both fragments were inserted into the
multiple cloning site of vector pEX18Ap [32]. The Gentamicin
resistance cassette of pPS858 [32] was excised using BamHI and
introduced into the BamHI and BglII site, respectively, between the
two flanking fragments. Constructs were confirmed by sequencing
and then transformed into the E. coli donor strain ST18 that was
used for conjugational transfer of the plasmids into P. aeruginosa
PAO1 as described previously [31].
After counter-selection on LB-agar plates containing 5%
sucrose and 80 mg/mL gentamycin, the obtained clones were
tested for carbenicillin sensitivity by replica plating. In order to
confirm the loss of plasmid borne DNA due to recombination
events, total DNA was isolated from the potential KO mutants and
used in PCR together with primers specific for internal sequences
of sacB and bla genes. Additionally the correct replacement of the
target gene by the gentamycin cassette was confirmed also by PCR
and sequencing. Primers located in approximately 200 base pairs
distance from the ends of the cassette and directed outwards were
Figure 1. The diaminopimelic acid pathway of lysine biosyn-
thesis. Left: the steps of the pathway are shown with the reactions
catalyzed by DapA and DapD indicated by blue and red arrows,
respectively. Right: Reactions catalyzed by dihydrodipicolinate synthase
(DapA, PA1010) and tetrahydrodipicolinate N-succinyltransferase
(DapD, PA3666). The structure of the substrate analogue 2-aminopi-
melate used as DapD substrate in this study is shown for comparison.
doi:10.1371/journal.pone.0031133.g001
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and downstream, respectively, from the target gene. The resulting
PCR products were isolated and sequenced.
Agarose bead preparation for infection with P. auriginosa
PAO1 wt and P. aeruginosa PAO1DdapA
Agarose beads were prepared using a method described
previously [33] with some modifications. P. aeruginosa PAO1
(ATCC 47085) and P. aeruginosa PAO1DdapA strains were cultured
over night at 37uC in LB and LB+Gentamycin (80 mg/ml),
respectively. After centrifugation at 4.000 rpm for 10 min the
sedimented bacteria were resuspended in 1 ml sterile PBS (pH 7.4)
and added to 5 ml 2% Agarose prewarmed to 50uC. The bacteria-
agarose mixture was transferred rapidly to 5 ml 50uC prewarmed
heavy white mineral oil. After intensive vortexing the mixture was
cooled on ice for 5 minutes followed by centrifugation at
4.000 rpm for 10 min. The resulting agarose beads were washed
three times in sterile PBS (pH 7.4). The load of bacteria in the
agarose beads was quantified by plating 10-fold serial dilutions on
Columbia blood agar plates. The inoculums for infection were
prepared by diluting the bead suspension with PBS (pH 7.4) to
2610
8 CFU/ml.
Lung infection of mice
For the infection studies we used female NMRI outbred mice at
the age of min. 6 weeks. The animals were anesthetized using a
Ketamin-Xylazin mixture applied by i.p. injection. Mice were
intratracheally infected with 50 ml of the bead suspension at a
concentration of 2610
8 CFU/ml resulting in 1610
7 CFU. This
study was carried out in strict accordance with the recommenda-
tions of the European Commission and the law for the Care and
Use of Laboratory Animals of the Government of the Federal
Republic of Germany. The protocol was approved by the
Committee on the Ethics of Animal Experiments of the Land-
esuntersuchungsamt of the government of Rheinland-Pfalz,
Federal Republic of Germany (Permit Number: 23 177-07/G09-
15-001).
Quantification of bacteria in the lung
72 hours after infection, the mice were sacrificed by CO2
inhalation. Lungs were isolated and homogenized through
microfilters. Mouse lung homogenates were diluted 1:1, 1:10
and 1:100 with sterile PBS (pH 7.4). The different dilutions were
plated on Columbia blood agar plates in case of P. aeruginosa PAO1
wildtype, and on agar plates containing Gentamycin for P.
aeruginosa PAO1DdapA. After overnight incubation at 37uC colony
counts were determined for each individual dilution.
Gene cloning, protein expression and purification
The DNA sequence coding for DapD (PA3666) from P.
aeruginosa PAO1 genomic DNA template (ATCC 47085D) was
amplified by PCR and cloned in the expression vector pET28a
(Novagen) using upstream NdeI and downstream HindIII sites
resulting in a cleavable six-histidine tag at the N-terminus. In this
construct, thrombin cleavage results in a recombinant protein with
three additional amino acids (Gly-Ser-His) at the N-terminus. The
genes coding for DapA (PA1010) and its homologues PA0223 and
PA4188 were amplified by PCR and cloned in pNIC28Bsa4
(GenBank Accession No. EF198106) using the LIC method
resulting in an N-terminal His6-tag with a TEV protease cleavage
site. Similarly, the expression construct of DapB (dihydropicolinate
reductase, DHDPR) from E. coli was based on pNIC28Bsa4
providing an N-terminal hexahistidine tag. All expression
constructs were confirmed by DNA sequencing.
Escherichia coli BL21(DE3) (Novagen) carrying the constructs
pET-His6PA3666 or pNIC-His6PA1010 was cultivated in 1.5 L
of LB medium supplemented with kanamycine (30 mg/ml) at
21uC. At an OD600 of 0.6–0.7 dapA or dapD gene expression was
induced by the addition of IPTG to 0.1 mM. After approximately
24 hours the cells were harvested and then re-suspended in a
buffer consisting of 10 mM Tris-HCl pH 8.0, 300 mM NaCl, and
10 mM imidazole. Cells were disrupted by freeze/thaw cycles,
lysozyme and DNaseI treatment followed by sonication. The
clarified lysates were loaded on a Ni-NTA column (Qiagen) with a
column volume of 1.5 ml. Pure recombinant proteins were eluted
in fractions containing 50–200 mM imidazole. The eluted proteins
were desalted on a Sephadex G-25 column (GE-Healthcare) and
retained in a buffer of 25 mM Tris-HCl pH 8.0, 150 mM NaCl.
In the case of DapD the N-terminal His6-tag was removed by
thrombin cleavage. This procedure resulted in homogeneous
DapD as verified by SDS PAGE. The pure His6-DapD and the
thrombin processed DapD proteins were concentrated to 26 mg/
ml by an Amicon centrifugation device with a 10 kDa MW cut-off.
Monomodal size distribution was confirmed by analyzing the
sample on a native polyacrylamide gel. In the case of DapA the
proteolytic cleavage by TEV protease did not remove the N-
terminal His6-tag efficiently, and His6-tagged protein was
therefore purified and used in all experiments. Aliquots of the
protein preparations were flash-frozen in liquid nitrogen and
stored at 280uC until further use. Analytical size exclusion
chromatography was carried out using a superdex-200 10/30
column (GE Healthcare, Uppsala, Sweden) with an equilibration
buffer of 25 mM Tris-HCl pH 8.0, containing 150 mM NaCl.
The column was calibrated with chymotrypsinogen-A (25 kDa),
ovalbumin (43 kDa), albumin (67 kDa), catalase (232 kDa) and
ferritin (440 kDa).
PA0223 and E. coli DapB were purified with affinity
chromatography utilizing the vector supplied N-terminal His-tag.
Elution fractions containing the pure proteins were passed through
a PD10 column (GE Healthcare, Uppsala, Sweden) and eluted
using a buffer consisting of 25 mM Tris-HCl pH 8.0, and
150 mM NaCl.
Enzyme assays
Purified recombinant DapD was assayed spectrophotometrical-
ly at 412 nm for succinyl-transferase activity by monitoring the
formation of free coenzyme-A derivatized by dithio-nitrobenzoate
[24] using L-2-aminopimelate as amino acid substrate. A racemic
mixture of 2-aminopimelate was purchased from Sigma, whereas
the pure enantiomeric forms of L- and D-2 aminopimelate were
obtained from Prof. Philip Cohen, University of Dundee.
Typically, the reactions were carried out in a total volume of
0.1 ml at 22uC. The reaction mixture contained 100 mM TRIS-
HCl pH 7.5, 2 mM MgCl2, succinyl-CoA at 0.1 mM, DTNB at
2.0 mM and DapD at 0.25 mM final concentrations. L-2-
aminopimelate was used in the range 0.5–15 mM and D-2-
aminopimelate at 2–4 mM. For the inhibition assays concentra-
tions of D-2AP of up to 70 mM were used. The reactions were
started by the addition of succinyl-CoA, and velocities were
derived from the initial slopes of the time courses recorded at
412 nm. Each measurement was carried out in triplicates.
The activity assays for PA1010 (DapA) and PA0223 were based
on the coupled assay using E. coli DHDPR as described by Kaur
et al. [20]. The measurements were carried out at 22uC in 100 ml
total volumes in 50 mM Tris-HCl at pH 8.0. The reaction
mixtures contained 1.5 mg/ml DapA, 23 mg/ml DHDPR,
DapD and DapA from Pseudomonas aeruginosa
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by the addition of S-aspartate-semialdehyde (Glycosyn, New
Zeeland) to 0.2 mM concentration. The absorbance was moni-
tored at 340 nm in a JASCO V-650 spectrophotometer to record
NADPH consumption. In the case of PA0223, enzyme concen-
trations of 1.5 mg/ml and 15 mg/ml were used.
Crystallization and data collection
Crystallization screening was carried out using the vapor
diffusion method and a Phoenix crystallisation robot. DapA
crystals were grown in hanging drops containing 2 ml of protein
solution (12.5 mg/ml) and 2 ml of reservoir solution (18% of
PEG6000, 0.2 M MgCl2, 0.1 M TRIS-HCl, pH 7.6). The crystals
used for diffraction analysis were cyo-protected by a short soak in a
buffer identical to the mother liquor containing 30% PEG6000.
Diffraction quality crystals of DapD were obtained by equilibrat-
ing a mixture of 2 ml of protein solution (26 mg/ml) and 2 mlo f
reservoir solution (19–20% of PEG3350, 0.3–0.4 M succinate,
pH 6.2) against the reservoir solution in hanging drops. Single
rod-shaped crystals appeared after 24–48 hours. These were flash-
frozen in liquid nitrogen without addition of any cryoprotectant.
The crystals of the CoA complex were produced by co-
crystallization in conditions identical to that of the apo-protein
by adding CoA (final concentration 10–15 mM) to the protein
solution for 10 minutes prior to crystallization. The crystals were
isomophous with those obtained for the apo-enzyme. Incubation
of PaDapD with formyl-CoA for 15 minutes resulted in crystals
that belong to the monoclinic space group (P21). These crystals
diffracted reproducibly to higher resolution. The complexes with
L-2-aminopimelate and D-2-aminopimelate were obtained by
soaking the monoclinic crystals in crystallization liquor containing
0.4 M of either D- or L-2-aminopimelate instead of succinate.
X-ray data to 2.95 A ˚ for the DapD apo-enzyme were collected
at the beamline ID14:4 of the European Synchrotron Radiation
Facility (ESRF, Grenoble, France) at 110 K. The dataset for the
binary complex DapD-CoA was collected at beamline ID14:1
(ESRF, Grenoble, France) at 110 K to 2.4 A ˚ resolution. The X-
ray data were processed and scaled with the programs MOSFLM
and SCALA from the CCP4 suite [34]. These crystals belong to
the tetragonal space group P41212 with cell dimensions
a=b=122.4 A ˚, and c=199.3 A ˚. A second dataset for the apo-
enzyme was collected from the monoclinic crystal form at
beamline I911-3 at MaxLab (Lund, Sweden) to 1.8 A ˚ resolution.
The diffraction datasets for the D- and the L-2-aminopimelate
complexes were collected at MaxLab (Lund, Sweden) at the
beamline I911-2 to 1.9 A ˚ and at I911-3 to 2.5 A ˚ resolution,
respectively (table 1). The datasets scaled well in the orthorhombic
Laue group P222, but a more detailed analysis indicated crystal
twinning. The true space group is P21, with a twinning operator (-
h, -k, l). The twinning fractions vary between crystals from 0.35 to
0.43.
A 1.6 A ˚ diffraction dataset from a DapA crystal was collected at
the beamline ID14:4 of the European Synchrotron Radiation
Facility (ESRF, Grenoble, France) at 110 K. DapA crystals belong
to the space group P1 with cell dimensions a=43.1 A ˚, b=51.7 A ˚,
c=140.3 A ˚, and a=95.7u, b=90.0u, c=113.3u. The statistics of
the data set are given in Table 1.
Molecular replacement and crystallographic refinement
The structure of PaDapD was determined initially by molecular
replacement in space group P41212 using the program MOLREP
[35]. A polyalanine model of the trimer of the putative
tetrahydropyridine-2-carboxylate N-succinyltransferase from Cam-
pylobacter jejuni (PDB code 2RIJ) with the cofactor and the solvent
atoms omitted was used as the search model. The best solution had
a score of 0.295 and an R-factor of 55.9%. In order to monitor the
refinement process, 5% of the X-ray data were removed for the
calculation of R-free. Initial cycles of restrained refinement using
Refmac5 [36] resulted in a drop of the R-factor by 15%. The
correctness of the molecular replacement solution was confirmed
by the appearance of electron density for the side chains specific
for PaDapD. Tight NCS restraints were applied throughout
refinement for the three subunits in the asymmetric unit.
The structure of PaDapD in the monoclinic crystal form was
determined by MOLREP [35] using the refined coordinates for
the PaDapD trimer from the tetragonal crystal form. The P21
crystals contain two trimers in the asymmetric unit. Since these
crystals exhibited various fractions of twinning, twin refinement as
implemented in Refmac5 [36] was employed. NCS restraints were
used throughout the refinement. Isotropic B-factor refinement was
used in all cases, except for the PaDapD complex with L-2-
aminopimelic acid. In this case TLS refinement was carried out in
the final cycles, resulting in a decrease of Rfree by 1.5%.
The structure of PaDapA was determined by molecular
replacement using the program MOLREP [35], and the
coordinates from Escherichia coli DapA (2OJP) [37] as search
model. The best solution contained four polypeptide chains in the
P1 unit cell, with a MOLREP score of 0.401 and R-factor of
0.489. The program Arp/warp [38] was used in the initial model
building and refinement steps.
Manual rebuilding of all models was carried out with the
program Coot, based on sigma-A weighted 2Fo-Fc and Fo-Fc
electron density maps [39]. Examination and adjustment of the
models were interspersed with rounds of refinement using
Refmac5 [36]. In the structures derived from the monoclinic
crystal form, i.e apo-enzyme, and the binary complexes with L-2
and D-2-aminopimelic acid, respectively, the C-terminal part of
the protein is disordered, and residues 330–344 were not modeled.
Water molecules were added based on peak heights, shape of the
electron density, temperature factor and capability to form
hydrogen bonds with surrounding protein residues and/or other
water molecules. Well defined difference electron density allowed
modeling of CoA and succinate for the CoA-succinate complex of
PaDapD. The final model of this complex contains three chains of
DapD, amino acid residues 1–245 and 251–343, three CoA and
succinate molecules and 147 water molecules. No electron density
was observed for the loop comprising residues 246–250. The
electron densities for the inhibitor/substrate molecules in the
binary complexes are well defined in all six subunits of the
asymmetric units, with the exception of subunit B of the DapD-L-
2-AP complex. The difference electron density for a ligand in the
active site of this subunit is not well defined, indicating low
occupancy, and we therefore did not model any bound substrate.
At the final stage anisotropic B-factors were used in the
refinement of the DapA structure as implemented in Refmac5.
The final model of PaDapA contains four polypeptide chains
(chain A: residues 1–291, and chains B, C and D: residues 2–291),
four chloride ions and 875 water molecules. Details of the
refinement and protein models are given in Table 1. The
crystallographic data have been deposited with the Protein Data
Bank, accession codes 3R5A, 3R5B, 3R5C, 3R5D for PaDapD
and 3QZE for the PaDapA.
Protein structures were analyzed and validated through the
MOLPROBITY server [40]. Structural comparisons were carried
out using the DALI algorithm [41] molecular contacts and
interacting surfaces were analyzed with the PISA server [42].
Figures were made using the program Pymol (http://www.pymol.
org).
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Characterization of Pseudomonas aeruginosa DapD
DapD from P. aerugionosa PAO1 was expressed in Escherichia coli
BL21(DE3) and purified to homogeneity. The size exclusion
chromatography suggests a trimeric structure in solution, corre-
sponding to a molecular mass of approximately 110 kDa.
Recombinant PaDapD was catalytically active as a succinyl
transferase with L-2-aminopimelic acid and succinyl-CoA as
substrates. Acetyl-CoA was not accepted as acyl-donor and
magnesium ions were not essential for catalysis. Various amino-
acids similar to 2-aminopimelate were tested, including L-lysine,
adipic acid, a-amino-adipic acid, L-e-acetyl-lysine, L-glutamate,
L-glutamine, L-norleucine, but catalytic activity was only observed
with 2-aminopimelate. The reaction is stereospecific with respect
to the amino donor substrate, i.e. only L-2 aminopimelate was
accepted as substrate with a KM of 7.0 mM and a Vmax of
105 mmol/min (figure 2A). D-2-aminopimelic acid is not accepted
as a substrate by PaDapD (figure 2B), but acts as a very weak
inhibitor (IC50.20 mM).
The structure of P. aeruginosa DapD
The structure of PaDapD was determined by x-ray crystallogra-
phy in its apo-form to 2.95 A ˚ and in complex with coenzyme A and
succinate to 2.3 A ˚ resolution in the spacegroup P41212. Incubation
of the protein in a solution of 20 mM formyl-CoA for 15 minutes
Table 1. Data collection and refinement statistics of the crystal structures of PaDapD and PaDapA.
Protein DapA DapD-CoA DapD-Apo DapD-D-AP DapD-L-AP
PDB code/file 3QZE 3R5C 3R5D 3R5A 3R5B
Space group P1 P41212P 2 1 P21 P21
Cell
a, 43.1 123.3 83.0 83.3 82.7
b, 51.7 123.3 102.0 101.9 100.4
c( A ˚) 140.3 198.8 134.9 135.7 133.6
a, b, c (u) 95.1, 90.0, 113.3 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.1, 90.0
Resolution (A ˚) 40.0-1.59 66.2-2.40 25-1.80 22-1.88 37-2.50
High Resolution shell 1.67-1.59 2.53-2.40 1.90-1.80 1.98-1.88 2.64-2.50
No. of unique reflections 139082 (20245) 60616 (8713) 190821 (18894) 173938 (19600) 72498 (9568)
I/s(I) 9.5 (3.1) 17.1 (2.6) 10.8 (2.8) 9.8 (2.3) 6.7 (3.2)
Redundancy 2.0 (2.0) 6.6 (6.7) 2.6 (1.9) 2.5 (2.3) 3.4 (3.1)
Completeness (%) 92.7 (92.2) 100 (100) 91.9 (62.7) 94.0 (72.8) 95.9 (87.7)
Rmerge (%) 5.3 (28.1) 11.2 (64.6) 5.7 (28.8) 5.9 (33.3) 14.4 (31.5)
Wilson B- value (A ˚2) 15.7 42.1 34.1 31.2 25.8
Refinement
Rcryst (%) 14.9 24.6 20.6 19.6 25.1
Rfree (%) 19.9 26.7 24 23.5 27.6
Number of protein atoms 8857 7773 14076 15196 14422
Number of CoA atoms 0 147 0 0 0
Number of substrate/inhibitor
atoms 0 24 0 72 60
O t h e r h e t e r o a t o m s 4 2022
Water molecules 875 147 715 1017 261
B-factor, A ˚2
Overall 17.2 41.2 26 45.3 23.0
Protein 16.5 41 26.2 45.2 23.0
Ligands - 67.5 - 52.9 27.3
Water 24.7 36.8 22.6 45.3 16.2
Rmsd from ideal geometry
Bond length (A ˚) 0.024 0.012 0.008 0.008 0.011
Bond angles (deg.) 2.023 1.4 1.0 1.1 1.2
Ramachandran Plot (%)
Residues in preferred regions 98 96.3 96.7 96.7 96.5
Residues in allowed regions 1.3 3.7 3.3 3.3 3.5
Outliers 0.7 0000
Values in parenthesis are for the highest resolution shell.
doi:10.1371/journal.pone.0031133.t001
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to the space group P21 that reproducibly diffracted better. The
structure of apo-PaDapD was subsequently determined and refined
to 1.8 A ˚ resolution using data from this crystal form. In the
tetragonal crystals (P41212) the asymmetric unit contained a trimer
of PaDapD, while in the monoclinic crystal form (P21) two such
trimers were found in the asymmetric unit. In all structures of
PaDapD the oligomerization mode and fold were the same and
resemble that of other DapD enzymes. Although the crystal packing
interactions are different in the tetragonal and monoclinic crystals,
the overall structure of the apo-PaDapD trimer is essentially
identical. Superposition of the individual subunits from different
crystal forms typically gives rmsd values of 0.5 A ˚, and superposition
of the trimers results in an rmsd of 0.55 A ˚.
The subunit of PaDapD consists of three domains, the N-
terminal globular domain, a central domain, and a C-terminal
Figure 2. Substrate specificity and reaction kinetics for DapD from P. aeruginosa. A. Lineweaver – Burk plot for the dependence of DapD on
the substrate L-2-aminopimelate. B. Activities of DapD in the presence of L-2-aminopimelate (L-2AP), D-2-aminopimelate (D-2AP) and a racemic
mixture of the two compounds (L-2AP+D-2AP) as substrates.
doi:10.1371/journal.pone.0031133.g002
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feature in this protein family and builds up the central domain
(residues 172–286) of each subunit. This domain also provides the
majority of intrasubunit interactions of the trimer. The N-terminal
domain consists of residues 1–171 and is rather large when
compared to other members of the family (figure 4). It can be
divided into two subdomains. The distal subdomain (residues 1–
133) comprises a four-stranded anti-parallel b-sheet, flanked by
three helices on one side and one helix on the opposite side of the
sheet that faces the central domain. The medial subdomain
(residues 134–171) comprises an a-helix and an anti-parallel b-
hairpin and is involved in inter-subunit interactions as in other
DapD structures known to date. The small C-terminal domain
(residues 287–344) folds in a curved, four stranded anti-parallel b-
sheet and two helices. This sheet extends the b-sheet of the central
domain and contributes to trimer formation.
Figure 3. The structure of P. aeruginosa DapD. A. Cartoon of the subunit of tetrahydrodipicolinate N-succinyltransferase (DapD). The N-terminal
domain is shown in blue, the central domain in green and the C-terminal domain in red. B & C: Views of the trimer of DapD. The three subunits are
coloured blue, brown and yellow. D. Surface illustration of the trimer of the DapD-coenzyme A-succinate complex. The substrate binding grooves are
formed between the left handed b-helix domains from adjacent subunits (blue and brown, respectively) of the trimer. Bound co-enzyme A and
succinate are shown as stick models in yellow. E. Interactions of DapD with the bound coenzyme-A and succinate. The two subunits contributing to
this active site are shown in blue and brown, respectively. Coenzyme-A is shown in yellow sticks and succinate in orange, while the amino acid side
chains involved in the interaction are depicted in light gray.
doi:10.1371/journal.pone.0031133.g003
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from each subunit are buried upon formation of the trimer.
Approximately 50 residues from each subunit contribute to
oligomerization. The trimer interface is predominantly polar with
26–28 hydrogen bonds and 12 salt bridges in every subunit contact
area.
The left-handed b-helix fold occurs in a large number of
proteins from viruses to plants and mammals. A Dali search using
the atomic coordinates of PaDapD identified several proteins with
a similar b-helical domain, with the closest relatives being the
putative DapD from Campylobacter (2RIJ) with a rmsd of 1.6 A ˚
based on 307 Ca atoms and DapD from M. tuberculosis (3FSX) with
277 equivalent residues and an rmsd of 1.3 A ˚.
The PaDapD-CoA-Succinate complex
The active site of PaDapD is located between neighbouring
subunits (figure 3D), and two subunits are involved in the
architecture of each active site. In each subunit interface a 35 A ˚
long narrow crevice is formed where the reactants are bound. The
residues contributing to the active site are from the central domain
and the C-terminal domain, whereas the N-terminal domain is not
directly involved in the formation of the active site.
Coenzyme A is bound in this narrow cleft formed at the
interface of two adjacent subunits (figure 3D & E). Both subunits
contribute to the interactions with CoA to a similar extent, with
about 350 A ˚ 2 of the surface area of CoA buried by each subunit.
CoA binds parallel to the trimer axis with the adenosine moiety
positioned between the C-terminal domains of adjacent subunits.
The pantetheine arm lies in the groove along the b-helix of two
central domains and the b-mercaptoethylamine moiety is facing a
cavity where the succinate molecule is bound (figure 3D & E). The
position and binding mode of CoA is similar to the one found in
MtDapD and other acyl-CoA transferases, described as a
‘‘hooked’’ conformation of the adenosine moiety and an extended
conformation of pantetheine arm [43]. The distance between the
ribose-39 phosphate and sulphur atom is 21.5 A ˚.
The adenine base of Coenzyme-A is inserted between the
guanidium group of Arg317(A) of one chain and Gly287(C) of a
neighbouring subunit. The carbonyl of Gly287(C) is at hydrogen
bond distance with the ribose 29 hydroxyl group. The 69 amino
group of the base is hydrogen-bonded with the main chain
carbonyl oxygen atom of Arg318(C) and the side chain oxygen
atom of Glu279(C). The backbone amino group of Ser320
interacts with the N1 nitrogen of the adenine ring. The 39
phosphate group forms hydrogen bonds to the e-amino moieties of
Lys289(A) and Lys304(A). The pyrophosphate is accessible to the
solvent (figure 3E) and does not form any interactions with the
protein. The pantheteine oxygen atoms form hydrogen bonds to
the main chain nitrogen atoms of Asn264 and Asn280.
Binding of CoA to PaDapD does not induce any large
conformational changes such as large scale domain re-arrange-
ments as indicated by the r.m.s.d. value upon superposition of the
subunits from the apo- and CoA complex of 0.55 A ˚. However
CoA binding causes a disorder-order transition in the enzyme. In
all structures of PaDapD that lack bound CoA, the last 15 residues
including an a-helix, are not resolved in the electron density,
whereas they are well defined in the PaDapD-CoA complex.
The crystal structure of the complex also contains a succinate
molecule bound next to the acceptor arm of the CoA in the active
site cleft (figure 3E), most likely due to the presence of 0.4 M
succinate in the crystallization buffer. Bound succinate interacts
with residues from both chains that make up the active site. One of
the carboxyl groups forms hydrogen bonds with the guanidium
moiety of Arg223 and the side chain of Ser241. The second
Figure 4. Evolutionary tree of DapD enzymes. The tree is based on a sequence alignment generated by the program Phylogenetic Tree
available at http:www.cbrg.ethz.ch/services. Known crystal structures are added as illustrations to protein fold-evolution. The N-terminal domains are
shown in blue, the central LbH-domains in orange and the C-terminal domains in red.
doi:10.1371/journal.pone.0031133.g004
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main chain carbonyl of Gly238. This pattern of hydrogen bonds
suggests however that one of the carboxyl groups of succinate or
the carboxyl group of Glu221 is protonated. The position of the
bound succinate corresponds well to the site of the succinyl-moiety
in the ternary complexes of MtDapD and EcDapD with the co-
substrate succinyl-CoA or its analogue, succinamide-CoA [26,29].
With the exception of the hydrogen bond to the side chain of
Glu221, the interactions between the enzyme and the bound
succinate in PaDapD are identical to those described for the
succinyl moiety in the MtDapD and EcDapD complexes.
The PaDapD -2-aminopimelate complex structures
Several attempts were made to obtain crystals of PaDapD with
the substrate L-2-aminopimelate or its isomer D-2-aminopimelate
without success, possibly due to the high concentrations (0.4–
0.6 M) of succinate in the crystallization buffer. Eventually, these
complexes could be prepared by soaking of monoclinic crystals of
PaDapD in crystallisation liquor, where succinate had been
replaced with either L- or D-2-aminopimelate.
The binding site of L- and D-2-aminopimelate in PaDapD is
located in the narrow groove formed between two subunits, and is
adjacent, but distinct from the binding sites for CoA and succinate
(figure 5). D-2-aminopimelate is bound to PaDapD in an extended
conformation, well defined in the electron density maps (figure 5).
In five of the six active sites in the crystal asymmetric unit the
interactions of this ligand are identical. The e-carboxyl group of
D-2-AP forms hydrogen bonds to the guanidinium groups of the
two arginine residues Arg181 and Arg193, and the appropriate
orientation of the side chains of these residues is ensured by a salt
bridge to the side chain of Asp168. The head a-carboxyl group is
anchored to the protein by hydrogen bonds to the main chain
amino group of Ala226 and the side chain of Asn209. The a-
amino group of the ligand is within hydrogen bonding distance to
one of the carboxylate oxygen atoms of Glu221. In the active site
located at the interface between subunits A and B, the binding
mode of the ligand is different. While the tail carboxyl group and
the carbon chain of D-2-AP interact in a similar manner with the
enzyme as in the other subunits, the binding modes of the a-
carboxyl- and a-amino groups are altered. The a-carboxyl group
occupies the position of the amino group observed in the majority
of the active sites and is within hydrogen bonding distance to the
carboxyl group of Glu221, indicating that one of these moieties is
protonated. The amino group points towards the side chain of
Asn209 and the main chain amino nitrogen atom of Ala226, but
does not form any hydrogen bonding interactions. There are no
indications in the electron density maps during refinement that the
active sites contain mixtures of these two binding modes, and the
reason why one of the active sites specifically selects this ligand
conformer remains unclear.
The crystallographic binding studies with the amino donor
substrate L-2-AP allowed straightforward fitting of the substrate in
the active sites of all subunits with the exception of chain B, where
the electron density is too weak for unambiguous modelling of
bound L-2-AP, indicating lower occupancy of the ligand. In three
of the subunits (chains A, D and E) the binding mode of the
substrate is very similar to those seen with its stereoisomer, D-2-
aminopimelate. The e-carboxyl group of L-2AP forms salt bridges
with the guanidinium groups of residues Arg18 and Arg19 and the
a-carboxylate of L-2AP forms hydrogen bonds to the side chain of
Asn209 and the main chain amino group of Ala226. In addition,
the a-amino group of L-2AP is also within hydrogen binding
distance to the side chain of Glu221. A comparison of the
PaDapD-L-2AP binary complex with the structure of the ternary
complex of the E. coli enzyme with coenzyme A and L-2AP [29]
reveals a very similar binding mode and conserved enzyme-ligand
interactions in both enzymes.
The binding of the substrate to the remaining two active sites (C
and F) is somewhat different from the one observed in chains A, D,
and E and can best be described as intermediate binding steps.
While the tail carboxyl group and parts of the alkyl chain of L-2-
AP are inserted into the active site, with the interactions of the
carboxyl tail to the two arginine residues Arg181 and Arg193
formed, the remaining part of the carbon chain and the head
group is still in contact with the bulk solution and does not yet
interact with protein residues. Thus, the ensemble of enzyme-
Figure 5. Ligand binding to PaDapD. A & B: OMIT electron density maps [44] for bound ligands L-2AP (A) and D-2AP (B), contoured at 1.6s.C&D :
Interactions of L-2AP (C) and D-2AP (D) at the active site of PaDapD. The two adjacent subunits that form an active site cleft are shown in blue and
brown colours. L-2AP is depicted in blue and D-2AP in green. Enzyme residues interacting with the ligands are shown in light grey.
doi:10.1371/journal.pone.0031133.g005
DapD and DapA from Pseudomonas aeruginosa
PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e31133ligand structures of PaDapD seen in the asymmetric unit might
represent snapshots of the binding process with binding to chain F
and C just after insertion of the e-carboxyl group and chains A, D
and E as the final steps with most or all interactions in place.
Intratracheal lung infection of NMRI mice with P.
aeruginosa and the DapA knock-out strain
For validation of DapA as potential target for novel drugs
against P. aeruginosa infections we attempted to create single gene
knockout strains of P. aeruginosa PAO1.
After three conjugations and screening of about 100 transcon-
jugants one dapA KO mutant was obtained and confirmed by
sequencing. NMRI mice were intratracheally infected with
agarose beads loaded with P. aeruginosa PAO1DdapA as described
in the method section. Mice were separated in groups per ten
animals each. The single groups were infected with bacterial beads
loaded with the mutant P. aeruginosa PAO1DdapA and PAO1 wild
type as control. 72 hours post infection lung homogenates were
plated in different dilutions for quantification of the bacterial load.
The mutant P. aeruginosa PAO1DdapA did not show decreased
numbers of total bacteria counts 72 hours after infection
compared to the wild type strain (figure 6).
Structure of Pseudomonas aeruginosa DapA (PA1010)
The crystal structure of PaDapA was determined by X-ray
crystallography to 1.6 A ˚ resolution. In contrast to most DapA
enzymes from Gram-negative bacteria PaDapA is not a homo-
tetramer but exists as a homodimer in solution and in the crystal.
Size exclusion chromatography suggested only one species with a
MW of 60 kDa, i.e. a dimeric structure. This finding is also
consistent with native polyacrylamid gel electrophoresis, which
only showed one species present in solution (figure 7). PaDapA is
also a dimer in the crystalline state, where the buried surface areas
at the dimer interface are 1500 A ˚ 2, whereas contacts to other
subunits in the crystal lattice involve surfaces of 300–400 A ˚ 2. The
observation of a dimeric subunit arrangement in the crystals is
consistent with the results obtained by size exclusion chromatog-
raphy in solution (data not shown). The basic fold of the subunit is
an (b/a)8 barrel with a C-terminal extension of approximately 60
amino acid residues folded into an additional small a-helical
domain. Comparison to the structure of PaDapA (PDB: 3PS7)
determined recently, albeit at the significantly lower resolution of
2.9 A ˚ [20], gives an rmsd value of 0.3 A ˚ for 290 aligned Ca atoms.
Characterisation of P. aeruginosa DapA (PA1010) and its
homologue, PA0223
The enzymatic assays using the recombinant gene product of
PA1010 verify that this enzyme functions as DapA, as the coupled
assay with DHDPR and S-ASA and pyruvate dependent
dihydrodipicolinate-synthase results in a specific activity of
21 mmol/min mg(protein) at 22uC. This value is comparable to
the activity of DapA from E. coli [23].
The two DapA homologues with unknown function found in
the P.aeruginosa PAO1 genome, PA0223 and PA4188 show high
levels of conservation in the active site. The heterologous
expression of PA4188 gave insoluble protein product and could
not be tested. PA0223 was purified utilizing the N-terminal His6-
tag and its folding integrity was confirmed by circular dichroism
spectroscopy. PA0223 did however not show any activity as
dihydrodipicolinate-synthase, even when tested at significantly
higher concentrations than PA1010 (DapA) in the assays.
Discussion
The structure of PaDapD shows the typical features of this fold
family, a left-handed parallel b-helix (LbH) domain, with
additional N- and C-terminal extensions (figure 4). The N-
terminal domains show large variations in structure among the
DapD enzymes although the substrates and the reaction catalyzed
are identical [26]. Likewise, the C-terminal domains show
variations in length, from about 20 to 70 residues, and
consequently range from a small b-hairpin addition to the LbH-
module in Enterococcus facalis to a complete domain with its own
hydrophobic core as in DapD from M. tuberculosis [26] and E. coli
[25]. PaDapD shows distinct features at the N- and C terminal
domains that are structurally different from those described for
DapD enzymes from Gram-negative bacteria and shows more
similarity to DapDs from M. tuberculosis and C. jejeuni (figure 4).
Structural basis of stereoselectivity
PaDapD is specific for L-2AP and the D-isomer is a weak
inhibitor of the enzyme, with an IC50.20 mM. The crystal
structures of PaDapD with L-2AP and D-2AP show that both
compounds are recognized by the enzyme, bind at the same
binding site and interact with the same enzyme residues. The high
Ki value of D-2AP does not allow a more detailed kinetic
characterisation of the mode of inhibition, but the fact that
substrate and inhibitor bind at the same site would suggest a
competitive inhibition mode.
As both isomers of 2-AP bind to the enzyme active site the
question arises as to why only the L-form serves as substrate. In the
absence of a crystal structure of a catalytically competent ternary
complex with enzyme, succinyl-CoA and substrate, we have
modelled a Michaelis complex (figure 8) based on superposition of
the structures of the PaDapD-CoA-succinate and PaDapD – L (or
D) -2AP complexes with that of the structure of DapD-succinyl-
CoA-pimelate and DapD-succinamide-L-2-AP [29]. In such a
model, the amino group of L-2-AP points towards the carbonyl
group of succinyl-CoA and is poised for a nucleophilc attack on
this carbon atom, i.e. for succinate transfer (figure 8A). The
interaction with the side chain of Glu221 could contribute to rate
enhancement by deprotonation of the substrate amino group as
was proposed for the E. coli enzyme [28,29]. A corresponding
model of the inhibited ternary complex shows that the amino
Figure 6. Assessment of the effect of PA1010 gene deletion in
vivo. Quantification of P. aeruginosa colonies grown in the lung of mice
intratracheally infected with agarose beads loaded with the P.
aeruginosa gene knock-out mutant (DPA1010) in comparison to PAO1
wildtype (wt).
doi:10.1371/journal.pone.0031133.g006
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nucleophilic attack on succinyl-CoA (figure 8B). We therefore
suggest that binding of D-2-AP in a conformation incompatible
with catalysis is the underlying basis for the discrimination of the
enzyme against this stereoisomer of 2-aminopimelate.
The dapA gene is not essential for infection in mice, as shown by
the ability of the P. aeruginosa DdapA mutant to grow in a mouse
acute infection model. A post-mortem analysis using structural
information for PaDapA and the genome of P. aeruginosa identified
two other orfs that may represent DapA homologues. PA0223
(Uniprot id: Q9I6R5) is a tetrameric enzyme (PDB:3NA8,
unpublished) that shows 30% sequence identity and 1.5 A ˚ rmsd
over 291 aligned Ca atoms when comparing to PaDapA (PA1010).
PA4188 is an uncharacterized protein (Uniprot id: Q9HWJ3) that
shows 27% sequence identity to PaDapA (figure 7). Enzymatic
assays using recombinant PA0223 show that this protein does not
act as a dihydropicolinate synthase in vitro, making it unlikely that it
can replace DapA (PA1010) in the PAO1DdapA mutant. The
reason for the ability of the PA1010 knockout mutant to grow in
the lungs of infected animals remains unclear, but our data suggest
that DapA is not a promising target for the design of novel
antibacterials against P. aeruginosa.
Figure 7. The structure of P. aeruginosa DapA. A. Size exclusion chromatography elution profile of PaDapA (PA1010) indicating that a single
species exists in solution. Based on the calibration curve (insert) the calculated molecular mass is 60 kDa. B. PaDapA (PA1010) purified sample
analyzed in native polyacrylamide gel electrophoresis indicating a single species. C. Stereo view of the active site of PaDapA located in the center of
the a/b barrel. Amino acid side chains forming the active site are indicated as stick models. Residues conserved in the three homologues PA1010,
PA0223 and PA4188 are shown in yellow, while the variable positions Thr44, Arg138 and Lys109 are indicated in purple. D. Sequence conservation in
DapA enzymes from Escherichia coli, Bacillus anthracis, Pseudomonas aeruginosa and the proposed DapA paralogues in the PAO1 genome PA0223
and PA4188. The active site residues in PaDapA (PA1010) are indicated with yellow or purple colour as in C.
doi:10.1371/journal.pone.0031133.g007
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